Is Cabaletta Bio, Inc. (CABA) a Buy, Sell, or Hold?
Cabaletta Bio, Inc.
NASDAQ:CABA
$2.75 USD
$0.08 (3.0%)
- Volume
- 576.46K
- Average Volume
- 4.94M
- Market Capitalization
- $448.4M
- P/E Ratio
- -1.40
- Dividend Yield
- 0.00%
- Price Target
- $14.00
- Year High
- $4.23
- Year Low
- $1.26
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.95
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Steven A. Nichtberger |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | CABA |
| CUSIP | 12674W109 |
| CIK | 0001759138 |
| Web | https://www.cabalettabio.com |
| Phone | 267 759 3100 |
| Currency | USD |
| Employees | 156 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.26 |
| Payout Ratio | 0.00 |
| Current Ratio | 2.95 |
| Quick Ratio | 2.95 |
| Cash Ratio | 2.81 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 0.00 |
| Cash Flow | -1.28 |
| Price / Cash Flow | -3.13 |
| Price / Book | 2.98 |
Price Target and Rating
| Average Stock Price Forecast | $14.00 |
| High Stock Price Forecast | $32.00 |
| Low Stock Price Forecast | $3.00 |
| Forecast Upside/Downside | -80.36% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 12 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-1.64 |
| Trailing P/E Ratio | -1.40 |
| PEG Ratio | -0.06 |
| P/E Growth | -0.06 |
| Net Income | $-167.86M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -131.58% |
| Return on Assets | -118.42% |
Financials Score
| AltmanZ Score | -2.57 |
| Piotroski Score | 1.00 |
| Working Capital | 80.81M |
| Total Assets | 148.15M |
| Ebit | -173.08M |
| Market Cap | 442.69M |
| Total Liabilities | 44.84M |
Poll Results
About Cabaletta Bio, Inc. (NASDAQ:CABA) Stock
Cabaletta Bio, Inc. is a biotechnology firm in the clinical development stage, specializing in the invention and advancement of sophisticated engineered T cell therapies. Its core mission is to treat autoimmune diseases where B cells are implicated in producing harmful autoantibodies. The company's unique chimeric autoantibody receptor (CAAR) T cell platform is engineered to precisely target and eradicate these specific disease-causing B cells. Leading its pipeline is DSG3-CAART, which is currently in Phase I clinical trials. This candidate is being assessed for efficacy in two distinct conditions: mucosal pemphigus vulgaris, an autoimmune blistering skin disorder, and Hemophilia A in patients exhibiting Factor VIII alloantibodies. Cabaletta's broader product candidate portfolio also inclu ... des MuSK-CAART, a preclinical asset aimed at a particular subset of myasthenia gravis patients; FVIII-CAART, in the discovery phase for another subgroup of Hemophilia A sufferers; and DSG3/1-CAART, also a discovery-stage program, designed for mucocutaneous pemphigus vulgaris. The company maintains strategic alliances, including a collaboration with the University of Pennsylvania and a research pact with The Regents of the University of California. Founded in 2017 as Tycho Therapeutics, Inc., it adopted the name Cabaletta Bio, Inc. in August 2018 and is based in Philadelphia, Pennsylvania.
Cabaletta Bio: The Market Sold The EULAR News, I'm Buying
2026-06-26 07:30:47
Cabaletta Bio (CABA) offers a de-risked, breadth-first CAR-T platform for autoimmune diseases, with strong EULAR 2026 data and a compelling $2.90/share entry point. CABA's rese-cel is advancing across five indications, with pivotal myositis and systemic sclerosis trials, clean safety profile, and automated manufacturing via Cellares. Recent $150M raise with participation from Eli Lilly and top biotech funds strengthens CABA's financial runway and strategic optionality, supporting a 2H27 BLA timeline.
2026-06-08 13:58:35
Cabaletta Bio, Inc. (CABA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
2026-06-03 07:00:00
83% of dermatomyositis patients in the Phase 1/2 RESET-Myositis study would have met the registrational primary endpoint; all these patients maintained their response off immunomodulators through latest follow-up, as long as 1.5 years
Is Cabaletta Bio (CABA) Stock Outpacing Its Medical Peers This Year?
2026-05-20 10:40:20
Here is how Cabaletta Bio, Inc. (CABA) and Curaleaf Holdings, Inc. (CURLF) have performed compared to their sector so far this year.
Cabaletta Bio (CABA) Upgraded to Buy: Here's Why
2026-05-18 13:01:06
Cabaletta Bio (CABA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Cabaletta Bio Q1 Earnings: More Positive Data Suggests CAR-T Can Work In Autoimmune
2026-05-14 10:46:41
Cabaletta Bio, Inc. is reaffirmed as a Buy despite recent share price volatility, driven by tangible clinical and manufacturing progress. Key catalysts include registrational trials for rese-cel in myositis, promising early data in myasthenia gravis and pemphigus vulgaris, and upcoming SLE and SSc readouts. Rese-cel's outpatient-friendly safety profile, removal of preconditioning, and scalable manufacturing platform position CABA for significant autoimmune market opportunities.
Cabaletta Bio Reports First Quarter 2026 Financial Results and Provides Business Update
2026-05-14 07:05:00
Preconditioning-free (PC-free) 6-to-9-month clinical data with a single infusion of the lowest dose of rese-cel in the RESET-PV study presented today at ASGCT 2026 Annual Meeting along with initial rese-cel translational data using Cellares' industrialized, automated manufacturing PC-free rese-cel initial data from the lowest dose RESET-SLE cohort expected in 1H26 Pivotal RESET-Myositis cohort with outpatient dosing option progressing to support first planned BLA submission for rese-cel next year Second pivotal indication for advancement to be announced after presentation of complete Phase 1/2 lupus and scleroderma data during June 2026 EULAR Congress PHILADELPHIA, May 14, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc.
Cabaletta Bio Reports First Quarter 2026 Financial Results and Provides Business Update
2026-05-14 07:05:00
Preconditioning-free (PC-free) 6-to-9-month clinical data with a single infusion of the lowest dose of rese-cel in the RESET-PV ® study presented today at ASGCT 2026 Annual Meeting along with initial rese-cel translational data using Cellares' industrialized, automated manufacturing
Frequently Asked Questions
-
What is the current Cabaletta Bio, Inc. (CABA) stock price?
-
Cabaletta Bio, Inc.(NASDAQ:CABA) stock price is $2.75 in the last trading session. During the trading session, CABA stock reached the peak price of $4.23 while $1.26 was the lowest point it dropped to. The percentage change in CABA stock occurred in the recent session was 3.0% while the dollar amount for the price change in CABA stock was $0.08.
-
CABA's industry and sector of operation?
-
The NASDAQ listed CABA is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of CABA?
-
Aimee Payne | Co-Founder & Co-Chair of Scientific Advisory Board
Michael C. Milone | Co-Founder & Co-Chair of Scientific Advisory Board
Gwendolyn K. Binder | President of Science & Technology
Qing Sarah Yuan | Chief Technology Officer
Michael Gerard | General Counsel & Secretary -
How many employees does CABA have?
-
Number of CABA employees currently stands at 156. CABA operates from 2929 Arch Street, Philadelphia, PA 19104, US.
-
Link for CABA official website?
-
Official Website of CABA is: https://www.cabalettabio.com
-
How do I contact CABA?
-
CABA could be contacted at phone #267 759 3100 and can also be accessed through its website. CABA operates from 2929 Arch Street, Philadelphia, PA 19104, US.
-
How many shares of CABA are traded daily?
-
The average number of CABA shares traded daily for last 3 months was 4.94M.
-
What is the market cap of CABA currently?
-
The market value of CABA currently stands at $448.4M with its latest stock price at $2.75